{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:05:01Z","timestamp":1786964701677,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Venetoclax has been approved recently for treatment of Acute myeloid leukemia (AML). Venetoclax is a BH3-mimetic and induces apoptosis via Bcl-2 inhibition. However, venetoclax\u2019s effect is still restrictive and a novel strategy is needed. In the present study, we demonstrate that sodium butyrate (NaB) facilitates the venetoclax\u2019s efficacy of cell death in AML cells. As a single agent, NaB or venetoclax exerted just a weak effect on cell death induction for AML cell line KG-1. The combination with NaB and venetoclax drastically induced cell death. NaB upregulated pro-apoptotic factors, Bax and Bak, indicating the synergistic effect by the collaboration with Bcl-2 inhibition by venetoclax. The combined treatment with NaB and venetoclax strongly cleaved a caspase substrate poly (ADP-ribose) polymerase (PARP) and a potent pan-caspase inhibitor Q-VD-OPh almost completely blocked the cell death induced by the combination, meaning that the combination mainly induced apoptosis. The combination with NaB and venetoclax also strongly induced cell death in another AML cell line SKNO-1 but did not affect chronic myeloid leukemia (CML) cell line K562, indicating that the effect was specific for AML cells. Our results provide a novel strategy to strengthen the effect of venetoclax for AML treatment.<\/jats:p>","DOI":"10.1038\/s41598-024-55286-0","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:03:43Z","timestamp":1709179423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate"],"prefix":"10.1038","volume":"14","author":[{"given":"Renshi","family":"Kawakatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Tadagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"55286_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"22","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 22, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"55286_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"55286_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"55286_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn, E. et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 37, 2187\u20132196 (2023).","journal-title":"Leukemia"},{"key":"55286_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"55286_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).","journal-title":"Blood Cancer J."},{"key":"55286_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo, S., Damato, A., Alfano, L. & Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Cancer Res. 37, 36 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"55286_CR8","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian, H. et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422\u20134429 (2010).","journal-title":"Blood"},{"key":"55286_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fonc.2015.00280","volume":"5","author":"K Pettit","year":"2015","unstructured":"Pettit, K. & Odenike, O. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front. Oncol. 5, 280 (2015).","journal-title":"Front. Oncol."},{"key":"55286_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126, 291\u2013299 (2015).","journal-title":"Blood"},{"key":"55286_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/cancers13061292","volume":"13","author":"S Hafezi","year":"2021","unstructured":"Hafezi, S. & Rahmani, M. Targeting BCL-2 in cancer: Advances, challenges, and perspectives. Cancers (Basel) 13, 1292 (2021).","journal-title":"Cancers (Basel)"},{"key":"55286_CR12","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","volume":"62","author":"H Cong","year":"2019","unstructured":"Cong, H. et al. Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives. J. Med. Chem. 62, 5750\u20135772 (2019).","journal-title":"J. Med. Chem."},{"key":"55286_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcdb.2014.07.002","volume":"35","author":"S Fulda","year":"2014","unstructured":"Fulda, S. Therapeutic exploitation of necroptosis for cancer therapy. Semin. Cell Dev. Biol. 35, 51\u201356 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"55286_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ceb.2004.09.011","volume":"16","author":"AL Edinger","year":"2004","unstructured":"Edinger, A. L. & Thompson, C. B. Death by design: Apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16, 663\u2013669 (2004).","journal-title":"Curr. Opin. Cell Biol."},{"key":"55286_CR15","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3390\/ijms15023145","volume":"15","author":"S Shimizu","year":"2014","unstructured":"Shimizu, S., Yoshida, T., Tsujioka, M. & Arakawa, S. Autophagic cell death and cancer. Int. J. Mol. Sci. 15, 3145\u20133153 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"55286_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrm2970","volume":"11","author":"P Vandenabeele","year":"2010","unstructured":"Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. & Kroemer, G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700\u2013714 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"55286_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"55286_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi, J., Gao, W. & Shao, F. Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends Biochem. Sci. 42, 245\u2013254 (2017).","journal-title":"Trends Biochem. Sci."},{"key":"55286_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","volume":"4","author":"Z Jin","year":"2005","unstructured":"Jin, Z. & El-Deiry, W. S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4, 139\u2013163 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"55286_CR20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.cdd.4401088","volume":"9","author":"G van Loo","year":"2002","unstructured":"van Loo, G. et al. The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell Death Differ. 9, 1031\u20131042 (2002).","journal-title":"Cell Death Differ."},{"key":"55286_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99\u2013163 (2007).","journal-title":"Physiol. Rev."},{"key":"55286_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0014-5793(99)01761-5","volume":"466","author":"Y Tsujimoto","year":"2000","unstructured":"Tsujimoto, Y. & Shimizu, S. Bcl-2 family: Life-or-death switch. FEBS Lett. 466, 6\u201310 (2000).","journal-title":"FEBS Lett."},{"key":"55286_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi, L. et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909\u2013916 (2011).","journal-title":"J. Clin. Oncol."},{"key":"55286_CR24","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163\u20133169 (2012).","journal-title":"Clin. Cancer Res."},{"key":"55286_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149\u20131159 (2010).","journal-title":"Lancet Oncol."},{"key":"55286_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488\u2013496 (2012).","journal-title":"J. Clin. Oncol."},{"key":"55286_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"55286_CR28","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater, A. P. et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J. Clin. Oncol. 38, 4042\u20134054 (2020).","journal-title":"J. Clin. Oncol."},{"key":"55286_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J Med."},{"key":"55286_CR30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"55286_CR31","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.3390\/cancers15143589","volume":"15","author":"E Oyogoa","year":"2023","unstructured":"Oyogoa, E., Traer, E., Tyner, J. & Lachowiez, C. Building on foundations: Venetoclax-based combinations in the treatment of acute myeloid leukemia. Cancers (Basel) 15, 3589 (2023).","journal-title":"Cancers (Basel)"},{"key":"55286_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2643-3230.BCD-23-0014","volume":"4","author":"CA Eide","year":"2023","unstructured":"Eide, C. A. et al. Clinical correlates of\u00a0venetoclax-based combination sensitivities to augment acute myeloid leukemia therapy. Blood Cancer Discov. 4, 452\u2013467 (2023).","journal-title":"Blood Cancer Discov."},{"key":"55286_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-023-06075-6","volume":"14","author":"C Xie","year":"2023","unstructured":"Xie, C. et al. Bcl-2 inhibition combined with PPAR\u03b1 activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis. 14, 573 (2023).","journal-title":"Cell Death Dis."},{"key":"55286_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF02897908","volume":"8","author":"Y Matsuzaki","year":"2003","unstructured":"Matsuzaki, Y., Sowa, Y., Hirose, T., Yokota, T. & Sakai, T. Histone deacetylase inhibitors-promising agents for \u201cgene-regulating chemoprevention\u201d and \u201cmolecular-targeting prevention\u201d of cancer-. Environ. Health Prev. Med. 8, 157\u2013160 (2003).","journal-title":"Environ. Health Prev. Med."},{"key":"55286_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0014-5793(03)01186-4","volume":"554","author":"T Hitomi","year":"2003","unstructured":"Hitomi, T., Matsuzaki, Y., Yokota, T., Takaoka, Y. & Sakai, T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett. 554, 347\u2013350 (2003).","journal-title":"FEBS Lett."},{"key":"55286_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canlet.2005.02.009","volume":"232","author":"J Sonnemann","year":"2006","unstructured":"Sonnemann, J. et al. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett. 232, 148\u2013160 (2006).","journal-title":"Cancer Lett."},{"key":"55286_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01.cej.0000195704.05246.fc","volume":"15","author":"SD Cho","year":"2006","unstructured":"Cho, S. D. et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur. J. Cancer Prev. 15, 57\u201363 (2006).","journal-title":"Eur. J. Cancer Prev."},{"key":"55286_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/sj.bjc.6601510","volume":"90","author":"R Kuefer","year":"2004","unstructured":"Kuefer, R. et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br. J. Cancer 90, 535\u2013541 (2004).","journal-title":"Br. J. Cancer"},{"key":"55286_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml1001954","volume":"2","author":"DM Fass","year":"2010","unstructured":"Fass, D. M. et al. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med. Chem. Lett. 2, 39\u201342 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"55286_CR40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/acschembio.8b00073","volume":"13","author":"MS Verma","year":"2018","unstructured":"Verma, M. S. et al. A common mechanism links activities of butyrate in the colon. ACS Chem. Biol. 13, 1291\u20131298 (2018).","journal-title":"ACS Chem. Biol."},{"key":"55286_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0378-4274(02)00422-8","volume":"139","author":"M MacFarlane","year":"2003","unstructured":"MacFarlane, M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 139, 89\u201397 (2003).","journal-title":"Toxicol. Lett."},{"key":"55286_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Investig. 104, 155\u2013162 (1999).","journal-title":"J. Clin. Investig."},{"key":"55286_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157\u2013163 (1999).","journal-title":"Nat. Med."},{"key":"55286_CR44","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.1038\/sj.onc.1207830","volume":"23","author":"S Nakata","year":"2004","unstructured":"Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5\/TRAIL-R2 and sensitize apoptosis induced by TRAIL\/APO2-L in human malignant tumor cells. Oncogene 23, 6261\u20136271 (2004).","journal-title":"Oncogene"},{"key":"55286_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/ijo.2021.5296","volume":"60","author":"T Yoshida","year":"2022","unstructured":"Yoshida, T. et al. Tumor necrosis factor-related apoptosis-inducing ligand is a novel transcriptional target of runt-related transcription factor 1. Int. J. Oncol. 60, 6 (2022).","journal-title":"Int. J. Oncol."},{"key":"55286_CR46","doi-asserted-by":"publisher","first-page":"D881","DOI":"10.1093\/nar\/gky1076","volume":"47","author":"FO Bagger","year":"2019","unstructured":"Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: A database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881\u2013D885 (2019).","journal-title":"Nucleic Acids Res."},{"key":"55286_CR47","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846255","volume":"19","author":"S Oki","year":"2018","unstructured":"Oki, S. et al. ChIP-Atlas: A data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 19, e46255 (2018).","journal-title":"EMBO Rep."},{"key":"55286_CR48","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1172\/JCI0215623","volume":"110","author":"VY Melnikov","year":"2002","unstructured":"Melnikov, V. Y. et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J. Clin. Investig. 110, 1083\u20131091 (2002).","journal-title":"J. Clin. Investig."},{"key":"55286_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1024116916932","volume":"8","author":"TM Caserta","year":"2003","unstructured":"Caserta, T. M., Smith, A. N., Gultice, A. D., Reedy, M. A. & Brown, T. L. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345\u2013352 (2003).","journal-title":"Apoptosis"},{"key":"55286_CR50","first-page":"300","volume":"2","author":"TT Rohn","year":"2009","unstructured":"Rohn, T. T., Kokoulina, P., Eaton, C. R. & Poon, W. W. Caspase activation in transgenic mice with Alzheimer-like pathology: Results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int. J. Clin. Exp. Med. 2, 300\u2013308 (2009).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"55286_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"55286_CR52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"55286_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115283","volume":"205","author":"K Hege Hurrish","year":"2022","unstructured":"Hege Hurrish, K. et al. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia. Biochem. Pharmacol. 205, 115283 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"55286_CR54","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10428194.2022.2042689","volume":"63","author":"BC Valdez","year":"2022","unstructured":"Valdez, B. C. et al. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma 63, 1634\u20131644 (2022).","journal-title":"Leuk Lymphoma"},{"key":"55286_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s002800050922","volume":"43","author":"MJ Egorin","year":"1999","unstructured":"Egorin, M. J., Yuan, Z. M., Sentz, D. L., Plaisance, K. & Eiseman, J. L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother. Pharmacol. 43, 445\u2013453 (1999).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"55286_CR56","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2174\/138945012804545443","volume":"13","author":"R Heidor","year":"2012","unstructured":"Heidor, R., Ortega, J. F., de Conti, A., Ong, T. P. & Moreno, F. S. Anticarcinogenic actions of tributyrin, a butyric acid prodrug. Curr. Drug Targets 13, 1720\u20131729 (2012).","journal-title":"Curr. Drug Targets"},{"key":"55286_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clnu.2010.09.012","volume":"30","author":"M Miyoshi","year":"2011","unstructured":"Miyoshi, M. et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin. Nutr. 30, 252\u2013258 (2011).","journal-title":"Clin. Nutr."},{"key":"55286_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ijc.10609","volume":"101","author":"ES Dyer","year":"2002","unstructured":"Dyer, E. S. et al. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int. J. Cancer 101, 496\u2013499 (2002).","journal-title":"Int. J. Cancer"},{"key":"55286_CR59","first-page":"579","volume":"22","author":"I Svechnikova","year":"2003","unstructured":"Svechnikova, I. et al. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int. J. Oncol. 22, 579\u2013588 (2003).","journal-title":"Int. J. Oncol."},{"key":"55286_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","volume":"11","author":"T Iannitti","year":"2011","unstructured":"Iannitti, T. & Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 11, 227\u2013249 (2011).","journal-title":"Drugs R D."},{"key":"55286_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu, T. et al. Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211\u2013214 (2013).","journal-title":"Science"},{"key":"55286_CR62","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1089\/neu.2017.5192","volume":"34","author":"G Kong","year":"2017","unstructured":"Kong, G. et al. The ketone metabolite \u03b2-hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. Neurotrauma 34, 2645\u20132655 (2017).","journal-title":"Neurotrauma"},{"key":"55286_CR63","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41598-018-36941-9","volume":"9","author":"S Chriett","year":"2019","unstructured":"Chriett, S. et al. Prominent action of butyrate over \u03b2-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci. Rep. 9, 742 (2019).","journal-title":"Sci. Rep."},{"key":"55286_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900001","volume":"63","author":"A Xing","year":"2019","unstructured":"Xing, A. et al. As a Histone deacetylase inhibitor, \u03b3-aminobutyric acid upregulates GluR2 expression: An in vitro and in vivo study. Mol. Nutr. Food Res. 63, e1900001 (2019).","journal-title":"Mol. Nutr. Food Res."},{"key":"55286_CR65","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"55286_CR66","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman, G. J. et al. VERONICA: Randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors\u2014Efficacy, safety, and biomarker results. Clin. Cancer Res. 28, 3256\u20133267 (2022).","journal-title":"Clin. Cancer Res."},{"key":"55286_CR67","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/cancers14061446","volume":"14","author":"DH Hoang","year":"2022","unstructured":"Hoang, D. H. et al. Synergy of venetoclax and 8-chloro-adenosine in AML: The interplay of rRNA inhibition and fatty acid metabolism. Cancers (Basel) 14, 1446 (2022).","journal-title":"Cancers (Basel)"},{"key":"55286_CR68","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-021-01076-4","volume":"14","author":"R Buettner","year":"2021","unstructured":"Buettner, R. et al. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J. Hematol. Oncol. 14, 70 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"55286_CR69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens, B. M. et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Cancer 1, 1176\u20131187 (2020).","journal-title":"Nat. Cancer"}],"updated-by":[{"DOI":"10.1038\/s41598-025-09484-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55286-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:37:36Z","timestamp":1757101056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55286-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55286"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55286-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-09484-z","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-09484-z","URL":"https:\/\/doi.org\/10.1038\/s41598-025-09484-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4975"}}